80% capital reduction and director election proposed, raising concerns over shareholder value dilution

GeneOne Life Science has convened an extraordinary general meeting on April 30, 2026, to propose an 80% capital reduction to cover accumulated deficits. The reduction will be executed by merging 5 common shares into 1 share, with the record date of May 16, 2026.
The purpose of the capital reduction is to improve the financial structure through deficit coverage, indicating a substantial accumulated loss. The stated capital will decrease from approximately 90.8 billion KRW to 18.1 billion KRW.
The meeting also includes the election of three inside directors: Lee Jun-kyu, Jun Kyung-ha, and Kim Hoon-bum. None of the candidates had transactions with the company in the last three years.
No shareholder return policies are included, and this reduction raises concerns about dilution of existing shareholders' equity. The company continues to report significant operating and net losses.
[AI Summary]The 80% capital reduction, while aimed at financial restructuring, is a negative event causing direct loss to existing shareholders. Given the large accumulated deficit and persistent operating losses, the short-term stock price is expected to be adversely affected, and investors should exercise caution.